1
Roger Petrus Gerebern Vandecruys, Eugene Marie Jozef Jans: Pregelatinized starch in a controlled release formulation. Janssen Pharmaceutica, Mary Appollina, December 23, 2003: US06667060 (81 worldwide citation)

The present invention concerns the use of pregelatinized starch to prevent dose-dumping from a hydrophilic controlled release formulation. It also concerns a hydrophilic controlled release formulation, more in particular a hydrophilic controlled release matrix formulation, and solid dosage forms pre ...


2
Roger Petrus Gerebern Vandecruys, Jozef Peeters, Marcus Eli Brewster: Pharmaceutical compositions comprising a basic drug compound, a surfactant, and a physiologically tolerable water soluble acid. Janssen Pharmaceutica, Kiera K Mathey, November 24, 2015: US09192577 (2 worldwide citation)

The invention provides a novel pharmaceutical composition comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base characterized in that the acid respectively base:drug compound ratio is at least 1:1 by weight.


3
Jérôme Emile Georges Guillemont, Paul Theodoor Agnes Stevens, Alex Herman Copmans, Jozef Peeters, Alfred Elisabeth Stappers, Roger Petrus Gerebern Vandecruys, Paul Stoffels: Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile. Janssen Pharmaceutica, December 29, 2009: US07638522 (2 worldwide citation)

The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation.


4
Jérôme Emile Georges Guillemont, Paul Theodoor Agnes Stevens, Alex Herman Copmans, Jozef Peeters, Alfred Elisabeth Stappers, Roger Petrus Gerebern Vandecruys, Paul Stoffels: Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile. Janssen Pharmaceutica, Rajiv S Shah, January 24, 2012: US08101629 (1 worldwide citation)

The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation.


5
Jérôme Emile Georges Guillemont, Paul Theodoor Agnes Stevens, Alex Herman Copmans, Jozef Peeters, Alfred Elisabeth Stappers, Roger Petrus Gerebern Vandecruys, Paul Stoffels: Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile. Janssen Pharmaceutica, Rajiv S Shah, June 7, 2011: US07956063 (1 worldwide citation)

The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation.


6
Roger Petrus Gerebern Vandecruys, Eugene Marie Jozef Jans: Pregelatinized starch in a controlled release formulation. Janssen Pharmaceutica, Kiera K Mathey, November 26, 2013: US08591945

The present invention concerns the use of pregelatinized starch to prevent dose-dumping from a hydrophilic controlled release formulation. It also concerns a hydrophilic controlled release formulation, more in particular a hydrophilic controlled release matrix formulation, and solid dosage forms pre ...


7
Peter Jozef Maria Van Remoortere, Roger Petrus Gerebern Vandecruys, Herman De Kock: Amorphous salt of a macrocyclic inhibitor of HCV. Janssen Pharmaceuticals, Andrea Jo Kamage, April 26, 2016: US09321758

The amorphous form of the sodium salt of the macrocyclic inhibitor of HCV of formula: as well as processes for manufacturing this salt.


8
Paul Marie Victor Gilis, Valentin Florent Victor De Conde, Roger Petrus Gerebern Vandecruys: Pellets having a core coated with an antifungal and a polymer. Janssen Pharmaceutical, Woodcock Washburn, December 16, 2003: US06663901

The present invention is concerned with pellets comprising a 710-1180 &mgr;m (16-25 mesh) sugar core, a coating film of a water-soluble polymer and an antifungal agent, and a seal coating layer wherein the residual concentration of dichloromethane is below 600 ppm; pharmaceutical dosage forms compri ...


9

10